Myostatin (also known as growth and differentiation
factor 8) is a secreted member of the
transforming growth factor-β (TGF-β) family that is mainly expressed in skeletal muscle, which is also its primary target tissue. Deletion of the
myostatin gene (Mstn) in mice leads to muscle
hypertrophy, and animal studies support the concept that
myostatin is a negative regulator of muscle growth and regeneration. However,
myostatin deficiency also increases bone formation, mainly through loading-associated effects on bone. Here we report a previously unknown direct role for
myostatin in osteoclastogenesis and in the progressive loss of articular bone in
rheumatoid arthritis (RA). We demonstrate that
myostatin is highly expressed in the synovial tissues of RA subjects and of human
tumor necrosis factor (TNF)-α transgenic (hTNFtg) mice, a model for human RA.
Myostatin strongly accelerates receptor activator of nuclear factor κB
ligand (RANKL)-mediated osteoclast formation in vitro through
transcription factor SMAD2-dependent regulation of nuclear factor of activated T-cells (NFATC1).
Myostatin deficiency or antibody-mediated inhibition leads to an amelioration of
arthritis severity in hTNFtg mice, chiefly reflected by less bone destruction. Consistent with these effects in hTNFtg mice, the lack of
myostatin leads to increased grip strength and less bone erosion in the K/BxN serum-induced
arthritis model in mice. The results strongly suggest that
myostatin is a potent therapeutic target for interfering with osteoclast formation and joint destruction in RA.